[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Pure red-cell aplasia is an isolated disorder of erythropoiesis that leads to the pment of severe, isolated anemia. In chronic kidney disease patients treated with n erythropoiesis stimulating agent (ESA), development of anti-erythropoietin antibodies s one of the leading causes of pure red-cell aplasia. It requires to stop treatment with ESA, but in the vast majority of cases immunosuppressive therapy is necessary to induce the disappearance of anti-erythropoietin antibodies. Isolated case reports suggest that, at least in some patients, treatments with ESA can be resumed after recovery from antibody-mediated pure red-cell aplasia.
Rossert
Jérôme
J
AP-HP (HEGP), université Paris-Descartes, INSERM U652, Paris, France. jerome.rossert@egp.aphp.fr
Casadevall
Nicole
N
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000906:Antibodies / Q000097:blood; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*
D000906:Antibodies; D011994:Recombinant Proteins; D004921:Erythropoietin